<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669185</url>
  </required_header>
  <id_info>
    <org_study_id>ZKS_0021PETN</org_study_id>
    <nct_id>NCT03669185</nct_id>
  </id_info>
  <brief_title>Pentaerithrityl Tetranitrate (PETN) for Secondary Prevention of Intrauterine Growth Restriction</brief_title>
  <acronym>PETN</acronym>
  <official_title>Pentaerithrityltetranitrat (PETN) Zur Sekundärprophylaxe Der Intrauterinen Wachstumsretardierung</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jena University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 10% of all pregnancies experience mal perfusion of the placenta resulting in
      fetal growth restriction (FGR) of the fetus. FGR is the most important cause of perinatal
      mortality and morbidity. Impaired placental function determined by insufficient
      transformation of the uterine arteries and mal-perfusion of the placenta is the leading cause
      of FGR. So far, there is no treatment option for pregnancies complicated by FGR and the
      clinical management is restricted to close monitoring, assessing for the optimal time point
      of delivery of the fetus threatened by intrauterine death. In a pilot study a risk reduction
      of 38% for the development of severe FGR and FGR or death could be demonstrated by giving the
      organic nitrate pentaerithrityl-tetranitrate (PETN) to patients recognized at risk for FGR by
      impaired uterine artery Doppler at mid gestation (Schleussner, 2014). To confirm these
      results this prospective randomized placebo controlled double-blinded multicentre trial, was
      initiated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Affecting approximately 10% of pregnancies, fetal growth restriction (FGR), is the most
      important cause of perinatal mortality and morbidity. Impaired placental function determined
      by insufficient transformation of the uterine arteries and mal-perfusion of the placenta is
      the leading cause of FGR. So far, there is no treatment option for pregnancy complicated by
      FGR and the clinical management is restricted to close monitoring, assessing for the optimal
      time point of delivering the fetus threatened by intrauterine death. In a prospective
      randomized controlled trial a risk reduction of 38% (relative risk RR=0.609, 95% CI 0.367 to
      1.011) for the development of IUGR and IUGR or death (RR=0.615, 95% CI 0.378 to 1.000) could
      be demonstrated by delivering the organic nitrate pentaerithrityl-tetranitrate (PETN) to
      patients recognized at risk for FGR by impaired uterine artery Doppler at mid gestation
      (Schleussner, 2014). To confirm these results a prospective randomized placebo controlled
      double-blinded multicentre trial was now initiated.

      Eligible patients are pregnant women at risk of developing FGR meeting the inclusion
      criteria: abnormal uterine artery Doppler ultrasound, defined by a mean PI exceeding 1.6,
      singleton pregnancy, informed consent and 19+0 to 22+6 weeks of gestation. The composite
      endpoint of severe FGR (&lt; birth weight below the 3rd centile) and intrauterine or neonatal
      death was defined as primary efficacy endpoint. and perinatal death. Key secondary endpoints
      are development of FGR (defined by birth weight &lt; 10th percentile), severe FGR (&lt; birth
      weight below the 3rd centile), intrauterine or neonatal death, placental abruption and
      preterm birth.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 26, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who develop intrauterine/fetal growth restriction or perinatal death.</measure>
    <time_frame>19 weeks of pregnancy - seventh day of life</time_frame>
    <description>Efficiency of PETN to prevent the development of intrauterine/fetal growth restriction or perinatal death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>severe morbidity</measure>
    <time_frame>19 weeks of pregnancy - seventh day of life</time_frame>
    <description>severe morbidity as a combined result of severe FGR (birth weight below the 3rd or 5th percentile) or perinatal death or premature abruption of placenta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>birth weight</measure>
    <time_frame>19-40 weeks of pregnancy</time_frame>
    <description>percentage of children with birth weight below the 3rd, 5th or 10th percentile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who developed FGR</measure>
    <time_frame>19-40 weeks of pregnancy</time_frame>
    <description>Number of participants who developed FGR, which necessitates delivery before 30 and 34 week of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>admission to NICU</measure>
    <time_frame>Birth to discharge from the hospital</time_frame>
    <description>rate of newborns transferred to neonatal intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infant outcome</measure>
    <time_frame>birth to discharge from NICU</time_frame>
    <description>rate of newborns with intraventricular cerebral haemorrhage (grade II - IV) or necrotizing enterocolitis, b.o.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of premature deliveries</measure>
    <time_frame>19 to 37 weeks of gestation</time_frame>
    <description>number of premature deliveries before completed 34 and 37 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>19 weeks of pregnancy - seventh day of life</time_frame>
    <description>number of perinatal deaths</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Fetal Growth Retardation</condition>
  <condition>Pregnancy Related</condition>
  <condition>Intrauterine Growth Restriction</condition>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebos, 2 times daily 1 tablet, intake max. 133 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentalong</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pentalong, 2 times daily 1 tablet, intake max. 133 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentalong</intervention_name>
    <description>Pentalong, 2 x daily 1 tablet, intake max. 133 days</description>
    <arm_group_label>Pentalong</arm_group_label>
    <other_name>Pentaeritrithyl tetranitrate</other_name>
    <other_name>Pentalong® 50 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebos, 2 x daily 1 tablet, intake max. 133 days</description>
    <arm_group_label>Placebos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  abnormal uterine artery Doppler at 19+0 to 22+6 weeks of gestation, defined by a mean
             pulsatility index (PI) Exceeding 1.6

          -  singleton pregnancy

          -  age&gt;/= 18 years

          -  informed consent

        Exclusion Criteria:

          -  known fetal chromosomal or suspected major structural defects at time of enrollment

          -  premature rupture of membranes at time of enrolment; maternal disease defined as
             contraindication for intake of PETN

          -  anamnestic known insensitivity to Pentalong® or its ingredients or to medications with
             similar chemical structure

          -  participation of the patient in another clinical trial (parallel or within the waiting
             period of a previous clinical trial)

          -  multiple pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women between pregnancy week 19+0 and 22+6</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja Groten, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universital Hospital Jena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Frauenklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Elisabeth und St. Barbara</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Halle</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berlin Charité Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berlin Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.uniklinikum-jena.de/geburtsmedizin/petn.html</url>
    <description>PETN Website</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PETN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

